Valneva Se (VALN) has released an update.
Valneva SE, a specialty vaccine company, will showcase its pioneering single-shot chikungunya vaccine, IXCHIQ®, and engage in discussions on public health threats at the 24th World Vaccine Congress in Washington D.C. The company is also a finalist for an award for IXCHIQ®, the first approved chikungunya vaccine. Additionally, Valneva and Pfizer’s collaborative Lyme disease vaccine candidate, VLA15, which is the furthest along in clinical development, will be presented.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.